Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine + Ipilimumab in Metastatic Melanoma
NCT02608437Phase 1Unknown
- Sponsor
- NIBIT Foundation
- Start
- Oct 2015
- Primary completion
- Oct 2016
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of guadecitabine in melanoma, sponsored by NIBIT Foundation. Primary endpoint: Maximum Tolerated Dose at 3 weeks. Status: unknown.
02
Drugs
guadecitabine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02608437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608437.